Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Corneal Transplantation Surgeons (US)

Articles with lock require a subscription to GLG News | Request a free trial
Barry SchechterJanuary 29, 2008
Bausch makes foray into presbyopic arena
Analysis of: Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
Author: Barry Schechter, Director of Corneal and External Diseases, Florida Eye Microsurgical Institute, Inc.
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
November 8, 2007
U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...
October 16, 2007
Interesting Approach to the Lucrative Dry Eye Market
Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 | www.pipelinereview.com
Author: GLG Expert Contributor
Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...
October 15, 2007
Restriction on Avastin distribution will add to Genenetech's bottom line.
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye | www.nytimes.com
Author: GLG Expert Contributor
       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...
October 15, 2007
Innovative Preventive Pulmonary Therapy Offers Promise of Increased Longevity for Young Cystic Fibrosis Patients
Analysis of: Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Inspire Pharmaceuticals' founding concept is based upon P2Y2 receptor agonist technology, now approaching fruition with groundbreaking cystic fibrosis (CF) clinicals.  Well tolerated three times daily nebulizer therapy with denufosol for young CF patients promises improved pulmonary function,...
July 16, 2007
FDA "Bifocal LASIK approval" not truly for bifocal vision.
Analysis of: FDA Approves Bifocal LASIK Surgery | www.medpagetoday.com
Author: GLG Expert Contributor
The FDA has just approved a "bifocal LASIK" technique from Advanced Medical Optics using their CustomVue Excimer laser platform.   It has been approved as " a new device". In actuality, it is neither a new device nor does it provide bifocal vision.
May 21, 2007
VEGF Trap continues to show promising data for wet AMD Treatment
Analysis of: Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting | www.pipelinereview.com
Author: GLG Expert Contributor
The VEGF Trap from Regeneron is a protein made up off human VEGF receptors fused to human immunoglobulin. This compound binds VEGF, preventing VEGF from binding to its natural receptors, interrupting the angiogenic cascade. The phase II study presented at 2007 ARVO showed promising results in patients...
May 21, 2007
Therapy with PDT is worthless in the world of anti-VEGF agents
Analysis of: Ranibizumab, PDT combination successfully treats neovascular AMD | www.osnsupersite.com
Author: GLG Expert Contributor
At the recent ARVO meeting, Italian researchers performing a randomized clinical trial on patients with wet AMD found that patients treated with photodynamic therapy (PDT) with Visudyne (verteporfin, Novartis) plus Lucentis(ranibizumab, Genentech) had a better visual result than patients treated with...
April 16, 2007
Prevention rules: The eye is window to the body PFE MRK SGP AZN DNA NVS BOL
Analysis of: Statins may reduce the risk of developing cataract, late AMD | www.osnsupersite.com
Author: GLG Expert Contributor
Data mining is a career choice for a growing number of academic Ophthalmologists and Optometrists. Rightly so, since newer analyses of well conceived population data bases found in the Blue Mountain or the Framingham cohorts continue to provide valuable epidemiologic information.Burgeoning case loads...
April 16, 2007
Cutting edge technology without a blade
Analysis of: Femtosecond laser dominates discussion at ESCRS winter meeting | www.osnsupersite.com
Author: GLG Expert Contributor
The ESCRS (European Society of Cataract & Refractive Surgery) actively engages Ophthalmologists who are seeking newer and better surgical procedures. This group self selects for innovative, aggressive, busy and entrepreneurial surgeons, as does its American counterpart, the ASCRS.Intralase technology...

Page : 1 2 3 Next1 to 10 of 28

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T05:45:17.133